Anti-CD38 IgG1 monoclonal antibody that targets CD38 on plasma cells and mediates ADCC, CDC, ADCP, and apoptosis while depleting CD38-positive immunosuppressive cells.
Human IgG1κ monoclonal antibody targeting CD38 on plasma cells; induces direct tumor cell killing via ADCC, CDC, ADCP, and apoptosis, and depletes CD38-positive immunosuppressive cells (Tregs, Bregs, MDSCs), enhancing antitumor immunity.
Anti-CD38 IgG1 binds CD38 on target cells and triggers immune effector killing—ADCC by NK cells, CDC via complement, ADCP by macrophages—and can also induce apoptosis.
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are gene-modified ex vivo to express a CD19-targeting CAR and infused to deplete CD19+ B-lineage cells (naive and memory B cells, plasmablasts), aiming to reduce autoantibody production and B cell–driven inflammation in SLE.
Autologous T cells are engineered ex vivo to express a CD19-targeting chimeric antigen receptor; upon infusion they recognize and kill CD19-positive B-lineage cells (naive and memory B cells, plasmablasts) via cytotoxic mechanisms, reducing autoantibody production and B cell–driven inflammation in SLE.
Anti-CD19 CAR T cells bind CD19 on target B cells and kill them via T-cell cytotoxic pathways (perforin/granzyme release and death-receptor apoptosis, e.g., Fas/FasL).
Bispecific T-cell engager (BiTE) that links CD3 on T cells to CD19 on B-cell blasts, triggering T-cell cytotoxicity.
A bispecific CD19×CD3 BiTE that binds CD3 on T cells and CD19 on B cells, bringing them into proximity to form an immune synapse and activate T-cell cytotoxicity, leading to perforin/granzyme-mediated lysis of CD19-positive B-lineage blasts independent of MHC.
Blinatumomab bridges CD3 on T cells to CD19 on target cells, forming an immune synapse and activating T-cell cytotoxicity that kills CD19+ cells via perforin/granzyme-mediated apoptosis (MHC-independent).
Humanized IgG1 monoclonal antibody against EGFR; binds EGFR to block ligand-induced activation, inhibiting downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling, and may elicit ADCC.
Humanized IgG1 monoclonal antibody against EGFR that blocks ligand-induced receptor activation and downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling, and may elicit ADCC to inhibit tumor growth.
IgG1 anti-EGFR antibody binds EGFR on target cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells) to mediate ADCC, killing the EGFR-expressing cells; it also blocks EGFR signaling (growth inhibition).